Robeco Institutional Asset Management’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-14,739
Closed -$3.62M 1067
2022
Q3
$3.62M Buy
14,739
+2,488
+20% +$672K 0.01% 568
2022
Q2
$3.03M Buy
12,251
+9,180
+299% +$2.48M 0.01% 594
2022
Q1
$1.02M Buy
3,071
+2,687
+700% +$827K ﹤0.01% 709
2021
Q4
$137K Buy
384
+9
+2% +$3.04K ﹤0.01% 854
2021
Q3
$122K Sell
375
-5,231
-93% -$1.77M ﹤0.01% 868
2021
Q2
$1.75M Sell
5,606
-4,175
-43% -$1.28M ﹤0.01% 702
2021
Q1
$3.12M Sell
9,781
-1,087
-10% -$348K 0.01% 614
2020
Q4
$3.52M Buy
10,868
+2,062
+23% +$570K 0.01% 599
2020
Q3
$2.44M Buy
+8,806
New +$2.54M 0.01% 607
2019
Q3
Sell
-87
Closed -$23K 1007
2019
Q2
$23K Sell
87
-41,737
-100% -$11.1M ﹤0.01% 954
2019
Q1
$11.9M Sell
41,824
-595
-1% -$198K 0.04% 439
2018
Q4
$13.8M Sell
42,419
-1,692
-4% -$588K 0.06% 356
2018
Q3
$19.8M Buy
44,111
+16,025
+57% +$6.32M 0.08% 296
2018
Q2
$11.5M Buy
+28,086
New +$10.2M 0.05% 378

Other funds holding ABMD

Robeco Institutional Asset Management's ABMD Position: Q4 2022 in Review

Robeco Institutional Asset Management sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 14,739 shares — an estimated $3.62M sold.

Robeco Institutional Asset Management first reported a position in ABMD in Q2 2018 and held it in 14 quarters. The position peaked at $19.8M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Robeco Institutional Asset Management reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Robeco Institutional Asset Management sold 14,739 Abiomed Inc shares in Q4 2022, an estimated $3.62M.
  • Robeco Institutional Asset Management first reported a position in Abiomed Inc in Q2 2018 and held it in 14 quarters.
  • Robeco Institutional Asset Management's Abiomed Inc position peaked at $19.8M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Robeco Institutional Asset Management's 13F filing for Q4 2022, filed 7 Feb 2023.